https://www.selleckchem.com/products/dcemm1.html
Published data support the safety of glatiramer acetate in patients with multiple sclerosis who are pregnant or breastfeeding, but long-term data are limited. We aimed to assess pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate. In-utero glatiramer acetate-exposed postmarketing pregnancy reports from 2019 to 2021 were extracted from Teva's pharmacovigilance database. Pregnancy data acquired prior to knowledge of pregnancy outcome or detection of congenital malformation (prospective reports) were used
Like
Comment
Share
